CJC-1295 + Ipamorelin vs MK-677 (Ibutamoren) vs MK-677
GHRH + GHS Stack · Ghrelin Mimetic
Here is how these two compounds compare, based on published research, not marketing claims.
CJC-1295
The GHRH-receptor side of the injectable stack; sustains GH release for days through the DAC modification.
Ipamorelin
The ghrelin-receptor side of the injectable stack; the most selective GH secretagogue with zero off-target hormonal effects.
MK-677
The oral monotherapy alternative; activates the ghrelin receptor in pill form with metabolic trade-offs (appetite, glucose).
CJC-1295
27 studies
2 human trials
Not FDA-Approved
Ipamorelin
134 studies
24 human trials
Not FDA-Approved
MK-677
134 studies
24 human trials
Not FDA-Approved
What it does
CJC-1295
Stretches a growth hormone signal that normally lasts minutes into one that lasts days. A small chemistry change attaches the molecule to albumin, a protein already circulating in the blood, which protects it from being broken down. In the published research, that translates to a half-life of roughly six to eight days, compared with minutes for the body's native GHRH.
Ipamorelin
Releases growth hormone without the cortisol or prolactin spike that older ghrelin agonists produced. The most receptor-selective compound in the GH secretagogue class for GHS-R1a, the ghrelin receptor itself. Comparable growth hormone elevation to GHRP-2 or GHRP-6 in head-to-head studies, without the hormonal collateral that made those compounds harder to study.
MK-677
Delivers growth hormone signaling through a pill rather than an injection: the only secretagogue in this class with practical oral bioavailability. Hits the same ghrelin receptor as the injectable compounds, but in a form the gut can absorb. Clinical trials (most notably Murphy et al. and Nass et al.) documented sustained nightly growth hormone and IGF-1 elevation across the 24-hour cycle, alongside the appetite increase and changes in blood sugar handling that ultimately contributed to the failed Alzheimer's trials and the compound's research-only status today.
How it works
CJC-1295
A modified version of the body's natural growth hormone signal. The modification makes it resist breakdown, so it stays active longer in the bloodstream.
Ipamorelin
Ipamorelin acts on a single receptor on the pituitary gland (the ghrelin receptor, GHS-R1a) and triggers growth hormone release without touching the cortisol axis, the prolactin axis, or the appetite signal that older compounds in this class also activated. Other GH secretagogues like GHRP-6 and hexarelin raise cortisol alongside GH, raise prolactin, and sharpen hunger. Ipamorelin does not.
MK-677
MK-677 binds the ghrelin receptor (GHS-R1a) on the pituitary gland and stimulates growth hormone release. The mechanism is functionally identical to injectable GH secretagogues like ipamorelin and GHRP-6, but the molecule is engineered for oral bioavailability. The body responds to the GH-releasing signal whether the trigger arrives by injection or by mouth. The downstream effect is increased GH followed by increased IGF-1 production from the liver.
How often
CJC-1295
In Phase I/II trials, CJC-1295 with DAC was given as a subcutaneous injection once or twice per week. The DAC modification (drug affinity complex) extends the active window to several days, which is what allows the once-or-twice-weekly schedule rather than daily injection.
Ipamorelin
In published human pharmacokinetic studies (Johansen 1999), ipamorelin was given as a subcutaneous injection with dose-dependent GH response measured over hours. The Beck 2014 Phase II post-surgical trial used repeated dosing over days. Clinical protocols typically use daily subcutaneous injection, though this frequency derives from clinical practice rather than from controlled dose-optimization trials.
MK-677
Oral administration in research protocols. Published studies use daily oral dosing over periods ranging from 8 weeks to 24 weeks. MK-677 is not FDA-approved for any therapeutic indication; no approved product contains ibutamoren mesylate.
How strong
CJC-1295
Stronger and more sustained. A bigger growth hormone pulse that lasts longer.
Ipamorelin
Moderate GH elevation with the cleanest hormonal profile in the secretagogue class. The GH pulse follows the body's natural pulsatile pattern rather than producing sustained elevation. The selectivity advantage is the pharmacological identity of the molecule.
MK-677
The oral GH secretagogue. Multiple short-term controlled studies (8 weeks to 6 months) demonstrate GH and IGF-1 elevation, body composition effects, bone turnover markers, and sleep quality improvements (Copinschi 1997 showed 50% increase in stage 4 sleep duration). Reversed diet-induced catabolism in healthy volunteers (Murphy 1998). Fat-free mass gains in obese men (Svensson 1998).
Main tradeoff
CJC-1295
Less pulsatile than the body's natural rhythm. Side effects, if they happen, stick around longer because the drug stays active longer.
Ipamorelin
The selectivity that makes ipamorelin distinctive is well documented, but clinical outcome data beyond the single Phase II post-surgical GI trial (Beck 2014) is absent. One of the most widely used peptides in clinical practice has almost no published outcomes data for the endpoints practitioners actually prescribe it for. The CJC-1295 plus ipamorelin combination has never been tested in a controlled comparison study despite being the most common clinical protocol.
MK-677
Oral convenience versus metabolic side effects is the core trade-off. MK-677 raises appetite (ghrelin is the hunger hormone), may elevate blood glucose and reduce insulin sensitivity, and causes water retention. The 24-week Murphy 2008 elderly hip-fracture study was discontinued due to a congestive heart failure signal in that population, the most concerning safety finding in the published literature. Whether the elderly CHF signal applies to healthy younger populations is not established. The compound has not passed Phase III trials despite decades of investigation. Compared to ipamorelin (the selective injectable alternative), MK-677 lacks the clean hormonal selectivity profile.
Best for
CJC-1295
- People who want fewer injections per week
- People who've plateaued on Sermorelin
- Anyone planning to stack with Ipamorelin (a popular combination because the two work through different receptors and amplify each other)
Ipamorelin
- Research interest in selective GH secretagogues with minimal off-target hormonal effects
- Research comparing GH secretagogue selectivity profiles across the class
- Research contexts where the CJC-1295 plus ipamorelin pairing is the protocol under study
MK-677
- Research interest in oral GH secretagogue mechanisms compared to injectable alternatives
- Research comparing sustained GH elevation (MK-677) versus pulsatile release (ipamorelin, sermorelin)
- Research contexts where the oral-versus-injectable administration question is central
How to choose
A good fit for CJC-1295
- Research on GHRH receptor-mediated GH release with extended pharmacokinetics
- Research contexts where the GHRH-side sustained baseline elevation is the variable under study
- Research requiring fewer weekly injections (once or twice weekly vs daily)
A good fit for Ipamorelin
- Research on selective ghrelin-receptor GH release with zero off-target hormonal effects
- Research comparing GH secretagogue selectivity profiles across the class
- Research contexts where hormonal cleanliness is the primary consideration
A good fit for MK-677
- Research on oral GH secretagogue mechanisms and ghrelin-receptor pharmacology
- Research contexts where injection avoidance is a primary constraint
- Research comparing sustained oral ghrelin activation versus injectable dual-receptor protocols
Consider all three
The CJC-1295 plus ipamorelin stack delivers complementary receptor activation (GHRH and ghrelin) through two injectable compounds; MK-677 delivers ghrelin-receptor activation alone in one daily pill. The stack approach targets a larger combined GH response from dual-receptor stimulation but requires injections and has no controlled study validating the combination. MK-677 offers oral convenience but with metabolic trade-offs (appetite, glucose, insulin sensitivity) that the ipamorelin side of the stack specifically avoids. The choice often comes down to delivery preference and side effect tolerance versus the theoretical advantage of complementary-receptor activation.
Dosing should be determined by a qualified physician who can evaluate individual circumstances. PSI does not provide personalized dosing guidance.
Official dosing references
- DailyMed(NIH drug labels)
- ClinicalTrials.gov
- PubMed
For readers who want the biology: here is the pathway each compound uses to signal the body. This section is optional. The comparison above covers the practical differences.
▶See the biology
- GHRH Receptor
- GHRH Receptor activates GHRH Signaling
- GHRH Signaling connects to Anterior Pituitary; Ghrelin Mimicry connects to Anterior Pituitary
- Anterior Pituitary connects to Growth Hormone Release
- Growth Hormone Release connects to IGF-1 Elevation
- GHS-R1a Receptor
- GHS-R1a Receptor activates Ghrelin Mimicry
CJC-1295 mimics GHRH to tell the pituitary gland to release growth hormone; the DAC modification extends activity from minutes to days.
Ipamorelin selectively binds the ghrelin receptor on pituitary somatotrophs to trigger growth hormone release without raising cortisol or prolactin.
MK-677 binds the ghrelin receptor (GHS-R1a) on the pituitary gland to trigger growth hormone release; in pill form rather than injection.
Research Evidence
MK-677 has the most individual human trial data: multiple controlled studies (8 to 24 weeks) with quantified endpoints across GH, IGF-1, body composition, bone turnover, and sleep. Ipamorelin has 48 published studies with human pharmacodynamic data confirming selectivity. CJC-1295 has Phase I/II pharmacokinetic data on sustained GH release. The CJC-1295 plus ipamorelin combination, despite being the most commonly prescribed GH peptide protocol, has never been studied in a controlled comparison trial. The evidence for the stack is mechanistic reasoning applied to individual compound data.
- 1.
If avoiding metabolic side effects is the priority, the CJC/Ipa stack has a cleaner profile.
- 2.
If convenience and avoiding injections matter most, MK-677 is oral.
- 3.
If published human data is the decision criterion, MK-677 has more.
- 4.
If clinical practice consensus matters, the CJC/Ipa stack is the most prescribed GH protocol in peptide therapy.
Key Limitations
- •No published study has tested CJC-1295 + ipamorelin as a combination.
- •MK-677's metabolic effects may limit long-term use.
- •The stack requires injections. MK-677 is oral.
- •Neither approach has outcome data proving GH elevation improves health markers.
Community Discussion
PSI monitors discussions across peptide research and biohacking communities. These are reported experiences, not clinical evidence.
CJC-1295 + Ipamorelin
"CJC-1295 with DAC gives you sustained growth hormone elevation for days"
Supported by published data
"Stacking CJC-1295 with ipamorelin is the gold standard for GH optimization"
Plausible but unproven
"It made me retain water and feel bloated"
Supported by published data
MK-677 (Ibutamoren)
"MK-677 increased my growth hormone levels significantly"
Supported by published data
"It made me hungry all the time and I gained fat"
Supported by published data
"I use it for better sleep and recovery"
Plausible but unproven
MK-677
"MK-677 increased my growth hormone levels significantly"
Supported by published data
"It made me hungry all the time and I gained fat"
Supported by published data
"I use it for better sleep and recovery"
Plausible but unproven
Safety Comparison
The CJC-1295 plus ipamorelin stack has the cleanest combined safety profile: CJC-1295's side effects are injection site reactions and water retention; ipamorelin specifically avoids cortisol, prolactin, and appetite changes. MK-677 carries the ghrelin pathway's metabolic effects (appetite increase, potential glucose and insulin sensitivity changes, water retention) and the elderly hip-fracture CHF signal (Murphy 2008). None of the three compounds has long-term human safety data. Compounded versions are not FDA-regulated.
CJC-1295 + Ipamorelin
Ipamorelin's selectivity keeps the stack clean. Minimal cortisol, prolactin, or appetite effects. Injectable.
MK-677 (Ibutamoren)
Appetite increase is common and significant. May elevate blood glucose and insulin. Water retention. Better-studied side effects due to more human data.
What the Research Suggests
The CJC/Ipa stack is clinically preferred for its clean side effect profile. MK-677 is preferred for convenience and published evidence. The right choice depends on whether you prioritize metabolic cleanliness or data and ease of use.